



New Results

Follow this preprint

## The phototrophic bacteria *Rhodomicrobium* spp. are novel chassis for bioplastic production

Eric M Conners, Karthikeyan Rengasamy, Arpita Bose

doi: <https://doi.org/10.1101/2023.05.17.541187>

This article is a preprint and has not been certified by peer review [what does this mean?].



Abstract

Info/History

Metrics

Preview PDF

### Abstract

Polyhydroxybutyrate (PHB) is a bio-based, biodegradable alternative to petroleum-based plastics. PHB production at industrial scales remains infeasible, in part due to insufficient yields and high costs. Addressing these challenges requires identifying novel biological chassis for PHB production and modifying known biological chassis to enhance production using sustainable, renewable inputs. Here, we take the former approach and present the first description of PHB production by two prosthecate photosynthetic purple non-sulfur bacteria (PNSB), *Rhodomicrobium vannielii* and *Rhodomicrobium udaipurense*. We show that both species produce PHB across photoheterotrophic, photoautotrophic, photoferrotrophic, and photoelectrotrophic growth conditions. Both species show the greatest PHB titers during photoheterotrophic growth on butyrate with dinitrogen gas as a nitrogen source (up to 44.08 mg/L), while photoelectrotrophic growth demonstrated the lowest titers (up to 0.13 mg/L). These titers are both greater (photoheterotrophy) and less (photoelectrotrophy) than those observed previously in a related PNSB, *Rhodopseudomonas palustris* TIE-1. On the other hand, we observe the highest electron yields during photoautotrophic growth with hydrogen gas or ferrous iron electron donors, and these electron yields were generally greater than those observed previously in TIE-1. These data suggest that non model organisms like

Rhodospirillum should be explored for sustainable PHB production and highlights utility in exploring novel biological chassis.

### Competing Interest Statement

The authors have declared no competing interest.

---

### Copyright

The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

[^ Back to top](#)

[← Previous](#)

[Next →](#)

Posted May 17, 2023.

[Download PDF](#)

[Email](#)

[Print/Save Options](#)

[Share](#)

[Supplementary Material](#)

[Citation Tools](#)

[Tweet](#)

[Like 0](#)

## COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

### Subject Areas

#### All Articles

Animal Behavior and Cognition

Biochemistry

Bioengineering

Bioinformatics

Biophysics

Cancer Biology

Cell Biology

Clinical Trials\*

Developmental Biology

Ecology

Epidemiology\*

Evolutionary Biology

Genetics

Genomics  
Immunology  
Microbiology  
Molecular Biology  
Neuroscience  
Paleontology  
Pathology  
Pharmacology and Toxicology  
Physiology  
Plant Biology  
Scientific Communication and Education  
Synthetic Biology  
Systems Biology  
Zoology

\*The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv ([submit.medrxiv.org](https://submit.medrxiv.org)). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).

Supported by **Chan  
Zuckerberg  
Initiative** 